Для специалистов
PanTum Detect − неинвазивный тест, который позволяет с точностью до 92% выявлять биохимические признаки более 60 видов онкологических заболеваний на ранних, доклинических стадиях. В том числе онкологические заболевания, для которых в настоящее время не существует программ скрининга. Подробнее
Тест-система «PanTum Detect» разработана немецкой компанией Zyagnum. Научным и производственным партнёром компании является ОДО «КомПродСервис». Производство тест-системы «PanTum Detect» размещено на базе УП «Хозрасчетное опытное производство Института биоорганической химии Национальной академии наук Беларуси».
Тест-система «PanTum Detect» разработана немецкой компанией Zyagnum. Научным и производственным партнёром компании является ОДО «КомПродСервис». Производство тест-системы «PanTum Detect» размещено на базе УП «Хозрасчетное опытное производство Института биоорганической химии Национальной академии наук Беларуси».
Это новый метод в ранней оценке пролиферативных новообразований, не имеющий мировых аналогов
Что такое тест PanTum Detect?
АНАЛИЗ КРОВИ НА антигены (APO10, TKTL1) – БИОЛОГИЧЕСКИЙ ФОН, ИССЛЕДУЕМЫЙ В ТЕСТЕ:
DNaseX (Аро10)
DNaseX представляет собой фермент, участвующий в апоптозе поврежденных клеток. Обычно он встречается в более высоких концентрациях в раковых клетках, в которых нарушен процесс апоптоза.
TKTL1
TKTL1 (сокращение от transketolase-like 1) представляет собой фермент - который участвует в пентозофосфатном пути метаболизма глюкозы. TKTL1 присутствует в более высоких концентрациях во многих раковых клетках.
CD-14 и -16
CD-14 и CD-16 являются контрольными параметрами, которые необходимы в лаборатории для качественной классификации образца. Эти параметры не имеют медицинского значения.
DNaseX представляет собой фермент, участвующий в апоптозе поврежденных клеток. Обычно он встречается в более высоких концентрациях в раковых клетках, в которых нарушен процесс апоптоза.
TKTL1
TKTL1 (сокращение от transketolase-like 1) представляет собой фермент - который участвует в пентозофосфатном пути метаболизма глюкозы. TKTL1 присутствует в более высоких концентрациях во многих раковых клетках.
CD-14 и -16
CD-14 и CD-16 являются контрольными параметрами, которые необходимы в лаборатории для качественной классификации образца. Эти параметры не имеют медицинского значения.
Интерпретация результата
Осуществляется с помощью программ искусственного интеллекта и технологии EDIM, использующей врожденную способность иммунной системы человека к поглощению злокачественных клеток.
зелёный Бланк отчёта (отрицательный результат)
жёлтый Бланк отчёта (положительный результат)
серый Бланк отчёта
(превышение одного из индикаторов метаболических процессов)
(превышение одного из индикаторов метаболических процессов)
синий Бланк отчёта
(результат не интерпретирован)
(результат не интерпретирован)
Цель проведения анализа «PanTum Detect»
Обнаружение предраковых или злокачественных опухолей на начальных этапах развития:
Повышает шансы на более эффективное лечение и выздоровление
Снижает риск осложнений, рецидивов и летального исхода
Выявление среди потенциально здоровых людей наличие опухолей с последующей специализированной диагностикой для подтверждения или исключения диагноза.
ДАННЫЙ ПРОЕКТ ВЫСТУПАЕТ ДОПОЛНЕНИЕМ К СУЩЕСТВУЮЩИМ ГОСУДАРСТВЕННЫМ ПРОГРАММАМ ОНКОСКРИНИНГА В РЕСПУБЛИКЕ БЕЛАРУСЬ
В 2019−2022 гг. проведены популяционные исследования и многочисленные клинические испытания на базе ведущих научно-практических и медицинских центров Беларуси и Германии, которые подтвердили высокие диагностические возможности теста PanTum Detect в онкоскрининге.
Так, в рамках исследования UKE (Университетской клиники Гамбург-Эппендорф), опубликованного в середине 2022 года, четко продемонстрирована эффективность анализа крови PanTum Detect для раннего выявления рака. В исследовании приняли участие 5000 потенциально здоровых людей в возрасте от 40 до 70 лет. В 9 из 10 случаев с положительным анализом крови подозрение на предраковую опухоль или онкологическое заболевание было подтверждено с помощью детальной диагностики.
Научные публикации:
1. Simon Burg, Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals. J Clin Med Img. 2022; V6(9): 1-12
2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
30. Krockenberger M et al: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007 Jan-Feb;17(1):101-6. University of Wuerzburg, Germany.
31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
33. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
34. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
35. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
36. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
37. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
38. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
39. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
40. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
41. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
42. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
43. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
44. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
45. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
46. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
47. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
48. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
49. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
50. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
51. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
52. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
53. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
54. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
55.Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.
31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
33. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
34. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
35. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
36. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
37. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
38. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
39. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
40. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
41. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
42. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
43. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
44. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
45. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
46. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
47. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
48. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
49. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
50. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
51. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
52. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
53. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
54. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
55.Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.
Мнение специалистов: